REC-4881 is an orally bioavailable allosteric MEK1/2 inhibitor under clinical development. NCI trial records describe active Phase 1b/2 evaluation in participants with familial adenomatous polyposis (FAP), and the agent is characterized as having potential antineoplastic activity. It is currently investigational rather than approved.
Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06005974 |
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation |
TERMINATED | PHASE2 |
| NCT05552755 |
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) |
RECRUITING | PHASE1/PHASE2 |
